Antibody mapping to domains of botulinum neurotoxin serotype A in the complexed and uncomplexed forms.
about
Botulinum Neurotoxin Is Shielded by NTNHA in an Interlocked ComplexLlama single domain antibodies specific for the 7 botulinum neurotoxin serotypes as heptaplex immunoreagents.Biophysical characterization of the stability of the 150-kilodalton botulinum toxin, the nontoxic component, and the 900-kilodalton botulinum toxin complex species.Extraction and inhibition of enzymatic activity of botulinum neurotoxins /B1, /B2, /B3, /B4, and /B5 by a panel of monoclonal anti-BoNT/B antibodiesBotulinum toxin type A products are not interchangeable: a review of the evidence.Epitope mapping of botulinum neurotoxins light chains.Immunization of mice with the non-toxic HC50 domain of botulinum neurotoxin presented by rabies virus particles induces a strong immune response affording protection against high-dose botulinum neurotoxin challenge.Identification of the factors that govern the ability of therapeutic antibodies to provide postchallenge protection against botulinum toxin: a model for assessing postchallenge efficacy of medical countermeasures against agents of bioterrorism and bEpitope characterization of sero-specific monoclonal antibody to Clostridium botulinum neurotoxin type AArchitecture of the botulinum neurotoxin complex: a molecular machine for protection and delivery.Trivalent vaccine against botulinum toxin serotypes A, B, and E that can be administered by the mucosal routeMolecular characterization of murine humoral immune response to botulinum neurotoxin type A binding domain as assessed by using phage antibody libraries.Immunogenicity of botulinum toxins.Assembly and function of the botulinum neurotoxin progenitor complexStructural biology. How a neurotoxin survives.Detection of type A, B, E, and F Clostridium botulinum neurotoxins in foods by using an amplified enzyme-linked immunosorbent assay with digoxigenin-labeled antibodiesProtein Structure Facilitates High-Resolution Immunological Mapping.Pharmacological differences and clinical implications of various botulinum toxin preparations: a critical appraisal.
P2860
Q27677462-DA11A63E-70F7-4030-B89F-A7DC696DD761Q33526251-85EB5A84-64F7-40F2-B1EF-6E068912457FQ33754195-D8A4E352-3A8C-415D-909F-3B875507AC77Q34074842-1F547BEE-3FBA-4181-90D2-786125575C36Q34352934-0CC3427B-0F22-42D2-B3FA-26CD21283549Q34393419-E7244321-7293-401E-8976-D62B8E9907D1Q35043107-A4DAC4B6-8505-415E-9EC3-ECDF7EA5E398Q35122868-A530238F-5979-4227-B2C1-F7F2D29840D5Q35754894-E6D7B2CD-EB13-406E-B5E3-898CC8071CB2Q35768158-3A8ACF87-D3CE-4C9A-90B6-C814B3FDB21BQ35913397-77E241DE-21D8-4D28-A42C-FB015A9F7B88Q36880684-7D18651F-DF2E-4238-BF1A-40E195936DE7Q38046142-D12D28F8-265F-4372-80C9-1A6D0FE163D8Q38067346-FE2E73F9-BA39-460B-8A57-B0E5CBB38DC0Q41846833-9A923D32-48FA-4A5B-8FF4-92374873E240Q41907289-34D3D3C8-A86D-4289-9653-388D00D7A2D0Q47098544-190B8CB1-088A-4823-AF04-A90C5BC23607Q55039946-24D12B26-DD46-42E2-A692-E869C945DAD7
P2860
Antibody mapping to domains of botulinum neurotoxin serotype A in the complexed and uncomplexed forms.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年学术文章
@wuu
1997年学术文章
@zh-cn
1997年学术文章
@zh-hans
1997年学术文章
@zh-my
1997年学术文章
@zh-sg
1997年學術文章
@yue
1997年學術文章
@zh
1997年學術文章
@zh-hant
name
Antibody mapping to domains of ...... mplexed and uncomplexed forms.
@en
Antibody mapping to domains of ...... mplexed and uncomplexed forms.
@nl
type
label
Antibody mapping to domains of ...... mplexed and uncomplexed forms.
@en
Antibody mapping to domains of ...... mplexed and uncomplexed forms.
@nl
prefLabel
Antibody mapping to domains of ...... mplexed and uncomplexed forms.
@en
Antibody mapping to domains of ...... mplexed and uncomplexed forms.
@nl
P2093
P2860
P1476
Antibody mapping to domains of ...... mplexed and uncomplexed forms.
@en
P2093
P2860
P304
P407
P577
1997-05-01T00:00:00Z